Dyadic International Expands Collaboration With Fermbox Bio to Accelerate Animal-Free Protein Commercialization
Dyadic International Inc. has announced a significant expansion of its strategic collaboration with Fermbox Bio, a biotech research and manufacturing company. The partnership aims to accelerate the commercialization of animal-free proteins and enzymes for life science, food and nutrition, and bioindustrial markets. Under the expanded agreement, Fermbox Bio will manufacture and commercialize a growing portfolio of Dyadic-developed proteins and enzymes utilizing both the Dapibus™ and C1 expression systems. Dyadic will co-commercialize these products globally, enhancing their ability to deliver sustainable, precision fermentation-derived bioproducts and meet the increasing demand for animal-free ingredients across key industries.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dyadic International Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9603438-en) on December 17, 2025, and is solely responsible for the information contained therein.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。